Breast Cancer Targets and Therapy

487 papers and 7.3k indexed citations i.

About

The 487 papers published in Breast Cancer Targets and Therapy in the last decades have received a total of 7.3k indexed citations. Papers published in Breast Cancer Targets and Therapy usually cover Oncology (283 papers), Cancer Research (194 papers) and Molecular Biology (104 papers) specifically the topics of Breast Cancer Treatment Studies (129 papers), HER2/EGFR in Cancer Research (87 papers) and Advanced Breast Cancer Therapies (52 papers). The most active scholars publishing in Breast Cancer Targets and Therapy are Yayun Liang, Salman M. Hyder, Sumi Dinda, Omar Farouk and Adam Brufsky.

In The Last Decade

Fields of papers published in Breast Cancer Targets and Therapy

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Breast Cancer Targets and Therapy. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Breast Cancer Targets and Therapy

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Breast Cancer Targets and Therapy. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Breast Cancer Targets and Therapy with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025